Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis

Figure 3

Effect of aprepitant or fasudil treatment on cardiac inflammation in viral-myocarditis. Paraffin-embedded heart sections were deparaffinized and stained with hematoxylin and eosin and were graded for cardiac inflammation. Cardiac inflammatory score of hearts derived from EMCV uninfected mice and infected mice, with and without aprepitant or fasudil treatment. Results are expressed as the mean ± SEM of 2 separate experiments (cardiac inflammatory score of, , uninfected versus infected, †, uninfected versus infected, with aprepitant pretreatment, ‡, uninfected versus infected, with aprepitant posttreatment, δ, uninfected versus infected, with fasudil pretreatment and, γ, uninfected versus infected, with fasudil posttreatment, ( for all ANOVA and Tukey’s post hoc test). Infected, with versus without pre- and postaprepitant treatment, or infected, with versus without fasudil pre- and posttreatment (all , ANOVA) ()). A representative H&E stained section from (a); (A) uninfected mouse, (B) EMCV-infected mouse, (C) EMCV-infected mouse with aprepitant pretreatment, (D) EMCV-infected mouse with aprepitant posttreatment, (E) EMCV-infected mouse with fasudil pretreatment, and (F) EMCV-infected mouse with fasudil posttreatment, depicting that EMCV-induced cardiac inflammation was not significantly impacted in aprepitant or fasudil treated mice.